
-
Incyte Corporation NasdaqGS:INCY Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Location: 1801 Augustine Cut-Off, Wilmington, DE, 19803, United States | Website: https://www.incyte.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
10.42B
Cash
2.409B
Avg Qtr Burn
N/A
Short % of Float
5.88%
Insider Ownership
2.22%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details Solid tumor/s, Cancer, Metastatic merkel cell carcinoma, Skin cancer | Approved Quarterly sales | |
Pemazyre® (pemigatinib) Details 8p11 myeloproliferative syndrome | Approved Quarterly sales | |
Niktimvo™ (axatilimab-csfr) Details Graft-versus-host disease | Approved Quarterly sales | |
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details Solid tumor/s, Cancer, Squamous cell carcinoma of the anal canal | BLA Submission | |
Tafasitamab (Monjuvi®) + Lenalidomide & Rituximab Details Follicular lymphoma, Relapsed/ refractory lymphoma | BLA Submission | |
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details Solid tumor/s, Cancer, Non-small cell lung carcinoma | BLA Submission | |
QD Ruxolitinib XR Details Myelofibrosis | NDA FDA meeting | |
Phase 3 Data readout | ||
Ruxolitinib Cream (Opzelura®) Details Atopic dermatitis | Phase 3 Data readout | |
Povorcitinib (JAK1) Details Hidradenitis suppurativa | Phase 3 Update | |
Ruxolitinib Cream (Opzelura®) Details Prurigo nodularis | Phase 3 Update | |
Povorcitinib (JAK1) Details Vitiligo | Phase 3 Initiation | |
Ruxolitinib Cream (Opzelura®) Details Hidradenitis suppurativa | Phase 3 Initiation | |
INCB57643 (BETi)+ruxolitinib Details Myelofibrosis | Phase 3 Initiation | |
Povorcitinib Details Asthma | Phase 2 Data readout | |
Povorcitinib Details Chronic spontaneous urticaria | Phase 2 Data readout | |
Ruxolitinib Cream (Opzelura®) Details Cutaneous Lichen Planus | Phase 2 Data readout | |
Povorcitinib (JAK1) Details Prurigo nodularis | Phase 2 Data readout | |
ALK2 + ruxolitinib Details Myelofibrosis | Phase 2 Data readout | |
INCA033989 (mCALR) Details Myelofibrosis | Phase 1 Data readout | |
INCB123667 [CDK2 Inhibitor] Details Solid tumor/s | Phase 1 Data readout | |
INCB99280/INCB99318 PD-L1 (oral) Details Solid tumor/s | Failed Discontinued | |
Parsaclisib + ruxolitinib Details Myelofibrosis | Failed Discontinued |